Patents by Inventor Jack L. Leonard
Jack L. Leonard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220332793Abstract: The invention provides highly potent and stable peptide mimetics of human DKK3b having numerous improved properties. The peptide mimetics of the invention are useful as therapeutics in the treatment of various diseases wherein inhibiting nuclear translocation of ?-catenin is therapeutic, including, but not limited to, cancer/proliferative, metabolic, osteoporosis, neurological, immunological, endocrinologic, cardiovascular, hematologic, and inflammatory diseases.Type: ApplicationFiled: April 21, 2022Publication date: October 20, 2022Inventor: Jack L. Leonard
-
Patent number: 11421008Abstract: The invention relates to novel therapeutic approaches to cancer treatment that exploits tumor suppressor functions of DKK3b by site-specific delivery of DKK3b. Novel therapeutics and methods for treating tumors and cancers utilizing DKK3b tumor suppressor functions are disclosed.Type: GrantFiled: September 6, 2019Date of Patent: August 23, 2022Assignee: University of MassachusettsInventors: Jack L. Leonard, Deborah M. Leonard, Karl J. Simin
-
Patent number: 11116851Abstract: The invention relates to the discovery of a vital new component of the Wnt pathway that regulates trafficking of ?-catenin to the cell nucleus and novel therapeutic approaches to cancer treatment. Disclosed herein is a previously unknown, essential component of the Wnt/?-catenin signaling pathway that governs the quantity of ?-catenin delivered to the cell nucleus. This intracellular inhibitor of ?-catenin signaling (IBS) is transcribed from a second transcriptional start site adjacent to exon 3 of the Dkk3 gene and is required for early mouse development. IBS captures ?-catenin destined for the nucleus in a complex with ?-TrCP that is bound to the actin cytoskeleton and unavailable for nuclear translocation.Type: GrantFiled: October 18, 2016Date of Patent: September 14, 2021Assignee: University of MassachusettsInventors: Jack L. Leonard, Karl J. Simin, Deborah M. Leonard
-
Publication number: 20200109180Abstract: The invention relates to novel therapeutic approaches to cancer treatment that exploits tumor suppressor functions of DKK3b by site-specific delivery of DKK3b. Novel therapeutics and methods for treating tumors and cancers utilizing DKK3b tumor suppressor functions are disclosed.Type: ApplicationFiled: September 6, 2019Publication date: April 9, 2020Inventors: Jack L. Leonard, Deborah M. Leonard, Karl J. Simin
-
Patent number: 10407478Abstract: The invention relates to novel therapeutic approaches to cancer treatment that exploits tumor suppressor functions of DKK3b by site-specific delivery of DKK3b. Novel therapeutics and methods for treating tumors and cancers utilizing DKK3b tumor suppressor functions are disclosed.Type: GrantFiled: May 17, 2016Date of Patent: September 10, 2019Assignee: University of MassachusettsInventors: Jack L. Leonard, Deborah M. Leonard, Karl J. Simin
-
Publication number: 20180272001Abstract: The invention relates to the discovery of a vital new component of the Wnt pathway that regulates trafficking of ?-catenin to the cell nucleus and novel therapeutic approaches to cancer treatment. Disclosed herein is a previously unknown, essential component of the Wnt/?-catenin signaling pathway that governs the quantity of ?-catenin delivered to the cell nucleus. This intracellular inhibitor of ?-catenin signaling (IBS) is transcribed from a second transcriptional start site adjacent to exon 3 of the Dkk3 gene and is required for early mouse development. IBS captures ?-catenin destined for the nucleus in a complex with ?-TrCP that is bound to the actin cytoskeleton and unavailable for nuclear translocation.Type: ApplicationFiled: October 18, 2016Publication date: September 27, 2018Inventors: Jack L. Leonard, Karl J. Simin, Deborah M. Leonard
-
Patent number: 9856301Abstract: The invention relates to novel therapeutic approaches to cancer treatment that exploits tumor suppressor functions of DKK3b by site-specific delivery of DKK3b. Novel therapeutics and methods for treating tumors and cancers utilizing DKK3b tumor suppressor functions are disclosed.Type: GrantFiled: October 10, 2014Date of Patent: January 2, 2018Assignee: University of MassachusettsInventors: Jack L. Leonard, Deborah M. Leonard, Karl J. Simin
-
Publication number: 20160326225Abstract: The invention relates to novel therapeutic approaches to cancer treatment that exploits tumor suppressor functions of DKK3b by site-specific delivery of DKK3b. Novel therapeutics and methods for treating tumors and cancers utilizing DKK3b tumor suppressor functions are disclosed.Type: ApplicationFiled: May 17, 2016Publication date: November 10, 2016Inventors: Jack L. LEONARD, Deborah M. LEONARD, Karl J. Simin
-
Publication number: 20150174200Abstract: The invention relates to novel therapeutic approaches to cancer treatment that exploits tumor suppressor functions of DKK3b by site-specific delivery of DKK3b. Novel therapeutics and methods for treating tumors and cancers utilizing DKK3b tumor suppressor functions are disclosed.Type: ApplicationFiled: October 10, 2014Publication date: June 25, 2015Inventor: JACK L. LEONARD
-
Publication number: 20080234365Abstract: Truncated thyroid hormone receptors ?TR?1 and ?TR?2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of ?TR?1 and ?TR?2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.Type: ApplicationFiled: May 20, 2008Publication date: September 25, 2008Inventors: Jack L. Leonard, Alan P. Farwell
-
Patent number: 7374890Abstract: Truncated thyroid hormone receptors ?TR?1 and ?TR?2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of ?TR?1 and ?TR?2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.Type: GrantFiled: April 12, 2004Date of Patent: May 20, 2008Assignee: University of MassachusettsInventors: Jack L. Leonard, Alan P. Farwell
-
Publication number: 20040265918Abstract: Truncated thyroid hormone receptors &Dgr;TR&agr;1 and &Dgr;TR&agr;2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of &Dgr;TR&agr;1 and &Dgr;TR&agr;2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.Type: ApplicationFiled: April 12, 2004Publication date: December 30, 2004Applicant: University of Massachusetts, a Massachusetts corporationInventors: Jack L. Leonard, Alan P. Farwell
-
Patent number: 6730472Abstract: Truncated thyroid hormone receptors &Dgr;TR&agr;1 and &Dgr;TR&agr;2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of &Dgr;TR&agr;1 and &Dgr;TR&agr;2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.Type: GrantFiled: June 28, 2001Date of Patent: May 4, 2004Assignee: University of MassachusettsInventors: Jack L. Leonard, Alan P. Farwell
-
Publication number: 20020090604Abstract: Truncated thyroid hormone receptors &Dgr;TR&agr;1 and &Dgr;TR&agr;2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of &Dgr;TR&agr;1 and &Dgr;TR&agr;2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.Type: ApplicationFiled: June 28, 2001Publication date: July 11, 2002Inventors: Jack L. Leonard, Alan P. Farwell
-
Patent number: 5849520Abstract: Methods of controlling the in vivo and in vitro expression of a heterologous protein by transfecting a cell with a first nucleic acid encoding the heterologous polypeptide, wherein at least one codon of mRNA transcribed from the first nucleic acid is replaced by the codon UGA, and a second nucleic acid operably linked to the first nucleic acid, the second nucleic acid directing the translation of the UGA codon as selenocysteine only when the cell can obtain selenium from the medium in which it is grown; and growing the cell under conditions in which the production of the polypeptide is controlled by the level of selenium available to the cell.Type: GrantFiled: May 30, 1995Date of Patent: December 15, 1998Assignee: University of Massachusetts Medical CenterInventors: Jack L. Leonard, Peter E. Newburger
-
Patent number: 5700660Abstract: The invention provides methods for determining the structure of a polypeptide by a) transfecting a cell with (i) a first nucleic acid encoding the polypeptide, wherein at least one, specific codon of mRNA transcribed from the first nucleic acid is replaced by the codon UGA, and (ii) a second nucleic acid, operably linked to the first nucleic acid, that directs the translation of the UGA codon as selenocysteine only when the cell can obtain selenium from the medium in which it is grown; b) growing the cell in selenium-containing growth medium under conditions in which the cell incorporates at least one selenocysteine residue into the polypeptide at a specific location; c) isolating the polypeptide from the cell or the growth medium; d) forming a crystal of the polypeptide; and e) performing X-ray crystallography on the crystal, wherein the selenocysteine residue is used to determine the structure of the polypeptide.Type: GrantFiled: June 7, 1995Date of Patent: December 23, 1997Assignee: University of Masachusetts Medical CenterInventors: Jack L. Leonard, Peter E. Newburger